A 6 Month Safety Extension Study of MBGS205

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

September 8, 2018

Study Completion Date

November 21, 2018

Conditions
Hypogonadotropic Hypogonadism
Interventions
DRUG

BGS649

Capsules will be taken weekly for a maximum of 24 weeks

Trial Locations (37)

Unknown

Mereo Research Site, Mobile

Mereo Research Site, Chandler

Mereo Research Site, Phoenix

Mereo Research Site, Scottsdale

Mereo Research Site, Anaheim

Mereo Research Site, Greenbrae

Mereo Research Site, Lincoln

Mereo Research Site, Los Angeles

Mereo Research Site, San Diego

Mereo Research Site, Bradenton

Mereo Research Site, DeLand

Mereo Research Site, Fort Myers

Mereo Research Site, Hialeah

Mereo Research Site, St. Petersburg

Mereo Research Site, Meridian

Mereo Research Site, Evansville

Mereo Research Site, Marrero

Mereo Research Site, Elkridge

Mereo Research Site, Henderson

Mereo Research Site, Las Vegas

Mereo Research Site, Albany

Mereo Research Site, Garden City

Mereo Research Site, Great Neck

Mereo Research Site, New York

Mereo Research Site, Rochester

Mereo Research Site, Charlotte

Mereo Research Site, Raleigh

Mereo Research Site, Winston-Salem

Mereo Research Site, Mt. Pleasant

Mereo Research Site, Nashville

Mereo Research Site, Dallas

Mereo Research Site, Fort Worth

Mereo Research Site, Pearland

Mereo Research Site, San Antonio

Mereo Research Site, West Jordan

Mereo Research Site, Norfolk

Mereo Research Site, Kenosha

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mereo BioPharma

INDUSTRY

NCT02908074 - A 6 Month Safety Extension Study of MBGS205 | Biotech Hunter | Biotech Hunter